Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood draw could spot bladder Cancer's return

NCT ID NCT07756437

Knowledge-focused Sponsor: AZ Sint-Lucas Gent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study is testing whether a blood test can find tiny pieces of tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer. Researchers will compare DNA from tumor tissue with DNA in blood samples taken during routine care. The goal is to see how well the test detects cancer-related mutations and whether it might predict recurrence or remission over two years. Participants do not receive any experimental treatment, and their doctors will not see the test results during the study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A blood-based circulating tumor DNA (ctDNA) test
What this could lead to
If successful, this blood test could help doctors detect cancer recurrence earlier and tailor treatments for bladder and upper tract cancers.
What could go wrong
This is an early-stage observational study, so the test may not prove accurate enough for routine use. It does not change treatment during the study, and results need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with muscle-invasive bladder cancer or suspected muscle-invasive upper tract urothelial carcinoma treated at AZ Sint-Lucas Gent. Participants must have available tumor tissue for DNA extraction and matched plasma samples obtained during routine clinical care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Histologically confirmed muscle-invasive bladder cancer or suspected muscle-invasive upper tract urothelial carcinoma, stage T2 or higher. * Availability of tumor tissue from transurethral resection of bladder tumor, ureteroscopic biopsy, biopsy of a metastatic lesion, or nephroureterectomy for DNA extraction. * Written informed consent provided. Exclusion Criteria: \- Concurrent active malignancy diagnosed within the past 5 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle invasive bladder cancer (MIBC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma Neoplasm, Residual renal pelvis/ureter urothelial carcinoma transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Muscle invasive bladder cancer (MIBC) Upper tract urothelial carcinoma Urothelial carcinoma (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Sint-Lucas Gent

    RECRUITING

    Ghent, East Flanders, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.